The Discovery of N-Cyclopropyl-4-Methyl-3-[6--(4-Methylpiperazin-1-Yl-4-Oxoquinazolin-3(4H)-Yl]Benzamide (Azd6703), a Clinical P38Alpha Map Kinase Inhibitor for the Treatment of Inflammatory DiseasesBrown, D.S., Cumming, J.G., Bethel, P., Finlayson, J., Gerhardt, S., Nash, I., Pauptit, R., Pike, K.G., Reid, A., Snelson, W., Swallow, S., Thompson, C.
(2012) Bioorg Med Chem Lett 22: 3879
- PubMed: 22608965
- DOI: https://doi.org/10.1016/j.bmcl.2012.04.116
- Primary Citation of Related Structures:
4A9Y, 4AA0, 4AA4, 4AA5, 4AAC
- PubMed Abstract:
A novel, potent and selective quinazolinone series of inhibitors of p38α MAP kinase has been identified. Modifications designed to address the issues of poor aqueous solubility and high plasma protein binding as well as embedded aniline functionalities resulted in the identification of a clinical candidate N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3(4H)-yl]benzamide (AZD6703). Optimisation was guided by understanding of the binding modes from X-ray crystallographic studies which showed a switch from DFG 'out' to DFG 'in' as the inhibitor size was reduced to improve overall properties.
AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.